Estrogens, MSI and Lynch syndrome-associated tumors

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1796, Issue 2, 2009, Pages 194-200

  Ferreira, Ana Monteiro ^a,b   Westers, Helga ^a   Albergaria, André ^b,c   Seruca, Raquel ^b,d   Hofstra, Robert M W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF MINHO   (Portugal)

^d University of Porto   (Portugal)

Author keywords

Estrogen; Estrogen receptor pathway; Lynch syndrome; Microsatellite instability; Mismatch repair system

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TAMOXIFEN;

APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL TUMOR; DISEASE ASSOCIATION; DNA DAMAGE; DNA METHYLATION; ENDOMETRIUM CANCER; FAMILIAL CANCER; HORMONE ACTION; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UTERUS CANCER;

ANIMALS; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MISMATCH REPAIR; ENDOMETRIAL NEOPLASMS; ESTROGENS; FEMALE; HUMANS; MICROSATELLITE INSTABILITY; RECEPTORS, ESTROGEN;

EID: 70349181786     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2009.06.004     Document Type: Review

References (78)

1. Chen G.G., Zeng Q., and Tse G.M. Estrogen and its receptors in cancer. Med. Res. Rev. 28 (2008) 954-974
2. Notarnicola M., Gristina R., Messa C., Cariola F., Fiorente P., Caruso M.L., Gentile M., and Di Leo A. Oestrogen receptors and microsatellite instability in colorectal carcinoma patients. Cancer Lett. 168 (2001) 65-70
3. Tsai M.J., and O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63 (1994) 451-486
4. Hall J.M., Couse J.F., and Korach K.S. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276 (2001) 36869-36872
5. Klein-Hitpass L., Tsai S.Y., Greene G.L., Clark J.H., Tsai M.J., and O'Malley B.W. Specific binding of estrogen receptor to the estrogen response element. Mol. Cell. Biol. 9 (1989) 43-49
6. Li X., Huang J., Yi P., et al. Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol. Cell. Biol. 24 (2004) 7681-7694
7. Huang J., Li X., Yi P., Bambara R.A., Hilf R., and Muyan M. Targeting estrogen responsive elements (EREs): design of potent transactivators for ERE-containing genes. Mol. Cell. Endocrinol. 218 (2004) 65-78
8. Velarde M.C., Zeng Z., McQuown J.R., Simmen F.A., and Simmen R.C. Kruppel-like factor 9 is a negative regulator of ligand-dependent estrogenreceptor alpha signaling in Ishikawa endometrial adenocarcinoma cells. Mol. Endocrinol. 21 (2007) 2988-3001
9. Roy D., Liehr J.G., and Estrogen D.N.A. damage and mutations. Mutat. Res. 424 (1999) 107-115
10. Nilsson S., and Gustafsson J.A. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2 (2000) 360-366
11. Geschickter C.F., Lewis D., and Hartman C.G. Tumors of the breast related to the oestrin hormone. Am. J. Cancer 21 (1934) 828-859
12. Rigoni-Stern D. Fatti statistici relativi alle malattie cancerose che servirono de base alle poche cose dette dal dott. Gior. Serv. Progr. Pat. Terap. 2 (1842) 507
13. Beatson G.T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new treatment with illustrative cases. Lancet 104 (1896)
14. (http://icmr.nic.in/bufebruary03.pdf) (ICMR bulletin, feb 2003 estrogen and breast cancer, vol 33, no.2)
15. Ayre J.E., and Bauld W.A. Thiamine deficiency and high estrogen findings in uterine cancer and in menorrhagia. Science 103 (1946) 441-445
16. IARC. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Supplement 7 (1987), IARC, Lyon, France 280-285
17. Russo J., and Russo I.H. The role of estrogen in the initiation of breast cancer. J. Steroid Biochem. Mol. Biol. 102 (2006) 89-96
18. Salama S.A., Kamel M., Awad M., Nasser A.H., Al-Hendy A., Botting S., and Arrastia C. Catecholestrogens induce oxidative stress and malignant transformation in human endometrial glandular cells: protective effect of catechol-O-methyltransferase. Int. J. Cancer 123 (2008) 1246-1254
19. Matthews J., and Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 3 (2003) 281-292
20. Katoh M. Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int. J. Oncol. 22 (2003) 209-212
21. Bouskine A., Nebout M., Mograbi B., Brücker-Davis F., Roger C., and Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 149 (2008) 565-573
22. Zhang L., Li X., Zhao L., Zhang L., Zhang G., Wang J., and Wei L. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J. Cell Biochem. 106 (2009) 553-562
23. Liehr J.G. Role of DNA adducts in hormonal carcinogenesis. Regul. Toxicol. Pharmacol. 32 (2000) 276-282
24. Liehr J.G. Genotoxicity of the steroidal oestrogens oestrone and oestradiol: possible mechanism of uterine and mammary cancer development. Hum. Reprod. Updat. 7 (2001) 273-281
25. Fernandez S.V., Russo I.H., and Russo J. Estradiol and its metabolites 4-hydroxyestradiol and 2-hydroxyestradiol induce mutations in human breast epithelial cells. Int. J. Cancer 118 (2006) 1862-1868
26. Wu H., Chen Y., Liang J., Shi B., Wu G., Zhang Y., Wang D., Li R., Yi X., Zhang H., Sun L., and Shang Y. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. Nature 438 (2005) 981-987
27. Slattery M.L., Potter J.D., Curtin K., Edwards S., Ma K.N., Anderson K., Schaffer D., and Samowitz W.S. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 61 (2001) 126-130
28. Campan M., Weisenberger D.J., and Laird P.W. DNA methylation profiles of female steroid hormone-driven human malignancies. Curr. Top. Microbiol. Immunol. 310 (2006) 141-178
29. Vasen H.F. Review article: the Lynch syndrome (hereditary nonpolyposis colorectal cancer). Aliment. Pharmacol. Ther. 26 Suppl. 2 (2007) 113-126
30. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., Meltzer S.J., Rodriguez-Bigas M.A., Fodde R., Ranzani G.N., and Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 58 (1998) 5248-5257
31. Notarnicola M., Gristina R., Messa C., Cariola F., Fiorente P., Caruso M.L., Gentile M., and Di Leo A. Oestrogen receptors and microsatellite instability in colorectal carcinoma patients. Cancer Lett. 168 (2001) 65-70
32. Breivik J., Lothe R.A., Meling G.I., Rognum T.O., Børresen-Dale A.L., and Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int. J. Cancer. 74 (1997) 664-669
33. Issa J.P., Ottaviano Y.L., Celano P., Hamilton S.R., Davidson N.E., and Baylin S.B. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7 (1994) 536-540
34. Baylin S.B., and Herman J.G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet. 16 (2000) 168-174
35. Newcomb P.A., Zheng Y., Chia V.M., Morimoto L.M., Doria-Rose V.P., Templeton A., Thibodeau S.N., and Potter J.D. Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res. 67 (2007) 7534-7539
36. Shen R., Tao L., Xu Y., Chang S., Van Brocklyn J., and Gao J.X. Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer from cancer. Int. J. Clin. Exp. Pathol. 2 (2009) 21-33
37. Wada-Hiraike O., Yano T., Nei T., Matsumoto Y., Matsumoto Y., Nagasaka K., Takizawa S., Oishi H., Arimoto T., Nakagawa S., Yasugi T., Kato S., and Taketani Y. The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br. J. Cancer. 92 (2005) 2286-2291
38. Miyamoto T., Shiozawa T., Kashima H., Feng Y.Z., Suzuki A., Kurai M., Nikaido T., and Konishi I. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology 147 (2006) 4863-4870
39. Sherman M.E. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod. Pathol. 13 (2000) 295-308
40. Amant F., Moerman P., Neven P., Timmerman D., Van Limbergen E., and Vergote I. Endometrial cancer. Lancet 366 (2005) 491-505
41. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., Ockene J., and Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
42. Chlebowski R.T., Hendrix S.L., Langer R.D., Stefanick M.L., Gass M., Lane D., Rodabough R.J., Gilligan M.A., Cyr M.G., Thomson C.A., Khandekar J., Petrovitch H., McTiernan A., and WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289 (2003) 3243-3253
43. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., Bonds D., Brunner R., Brzyski R., Caan B., Chlebowski R., Curb D., Gass M., Hays J., Heiss G., Hendrix S., Howard B.V., Hsia J., Hubbell A., Jackson R., Johnson K.C., Judd H., Kotchen J.M., Kuller L., LaCroix A.Z., Lane D., Langer R.D., Lasser N., Lewis C.E., Manson J., Margolis K., Ockene J., O'Sullivan M.J., Phillips L., Prentice R.L., Ritenbaugh C., Robbins J., Rossouw J.E., Sarto G., Stefanick M.L., Van Horn L., Wactawski-Wende J., Wallace R., Wassertheil-Smoller S., and Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
44. Takahashi M., Shimomoto T., Miyajima K., Yoshida M., Katashima S., Uematsu F., Maekawa A., and Nakae D. Effects of estrogens and metabolites on endometrial carcinogenesis in young adult mice initiated with N-ethyl-N′-nitro-N-nitrosoguanidine. Cancer Lett. 211 (2004) 1-9
45. Howell S.J., Johnston S.R., and Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab. 18 (2004) 47-66
46. Smith C.L., and O'Malley B.W. Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocr. Rev. 25 (2004) 45-71
47. Polin S.A., and Ascher S.M. The effect of tamoxifen on the genital tract. Cancer Imaging 8 (2008) 135-145
48. Potter J.D. Hormones and colon cancer. J. Natl. Cancer Inst. 87 (1995) 1039-1040
49. Grodstein F., Newcomb P.A., and Stampfer M.J. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am. J. Med. 106 (1999) 574-582
50. D'Errico I., and Moschetta A. Nuclear receptors, intestinal architecture and colon cancer: an intriguing link. Cell. Mol. Life Sci. 65 (2008) 1523-1543
51. McMichael A.J., and Potter J.D. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J. Natl. Cancer Inst 65 (1980) 1201-1207
52. Peipins L.A., Newman B., and Sandler R.S. Reproductive history, use of exogenous hormones, and risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 6 (1997) 671-675
53. Chen M.J., Longnecker M.P., Morgenstern H., Lee E.R., Frankl H.D., and Haile R.W. Recent use of hormone replacement therapy and the prevalence of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 227-230
54. Kadiyska T., Yakulov T., Kaneva R., Nedin D., Alexandrova A., Gegova A., Savov A., Mitev V., and Kremensky I. Vitamin D and estrogen receptor gene polymorphisms and the risk of colorectal cancer in Bulgaria. Int. J. Colorectal Dis. 22 (2007) 395-400
55. Foley E.F., Jazaeri A.A., Shupnik M.A., Jazaeri O., and Rice L.W. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res. 60 (2000) 245-248
56. Jassam N., Bell S.M., Speirs V., and Quirke P. Loss of expression of oestrogen receptor beta in colon cancer and its association with Dukes' staging. Oncol. Rep. 14 (2005) 17-21
57. Kennelly R., Kavanagh D.O., Hogan A.M., and Winter D.C. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol. 9 (2008) 385-391
58. Jazaeri A.A., Nunes K.J., Dalton M.S., Xu M., Shupnik M.A., and Rice L.W. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene 20 (2001) 6965-6969
59. Fu X.D., and Simoncini T. Extra-nuclear signaling of estrogen receptors. IUBMB Life 60 (2008) 502-510
60. Song R.X., Zhang Z., Chen Y., Bao Y., and Santen R.J. Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology 148 (2007) 4091-4101
61. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., Fiorentino R., Varricchio L., Barone M.V., and Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. EMBO J. 20 (2001) 6050-6059
62. Márquez D.C., and Pietras R.J. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 20 (2001) 5420-5430
63. Sun M., Paciga J.E., Feldman R.I., Yuan Z., Coppola D., Lu Y.Y., Shelley S.A., Nicosia S.V., and Cheng J.Q. Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. Cancer Res. 61 (2001) 5985-5991
64. Duan R., Xie W., Li X., McDougal A., and Safe S. Estrogen regulation of c-fos gene expression through phosphatidylinositol-3-kinase-dependent activation of serum response factor in MCF-7 breast cancer cells. Biochem. Biophys. Res. Commun. 294 (2002) 384-394
65. Razandi M., Pedram A., Merchenthaler I., Greene G.L., and Levin E.R. Plasma membrane estrogen receptors exist and functions as dimers. Mol. Endocrinol. 18 (2004) 2854-2865
66. Lee Y.R., Park J., Yu H.N., Kim J.S., Youn H.J., and Jung S.H. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells. Biochem. Biophys. Res. Commun. 336 (2005) 1221-1226
67. Dery M.C., Leblanc V., Shooner C., and Asselin E. Regulation of Akt expression and phosphorylation by 17beta-estradiol in the rat uterus during estrous cycle. Reprod. Biol. Endocrinol. 1 (2003) 47
68. Chen B., Pan H., Zhu L., Deng Y., and Pollard J.W. Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase->AKT->GSK-3beta->cyclin D1->pRB pathway to block uterine epithelial cell proliferation. Mol. Endocrinol. 19 (2005) 1978-1990
69. Guzeloglu Kayisli O., Kayisli U.A., Luleci G., and Arici A. In vivo and in vitro regulation of Akt activation in human endometrial cells is estrogen dependent. Biol. Reprod. 71 (2004) 714-721
70. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids. 65 (2000) 227-251
71. Edwards D.P. The role of coactivators and corepressors in the biology and mechanism of action of steroid hormone receptors. J. Mammary Gland Biol. Neoplasia 5 (2000) 307-324
72. Laganière J., Deblois G., Lefebvre C., Bataille A.R., Robert F., and Giguère V. From the cover: location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11651-11656
73. Carroll J.S., Liu X.S., Brodsky A.S., Li W., Meyer C.A., Szary A.J., Eeckhoute J., Shao W., Hestermann E.V., Geistlinger T.R., Fox E.A., Silver P.A., and Brown M. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 122 (2005) 33-43
74. Carroll J.S., and Brown M. Estrogen receptor target gene: an evolving concept. Mol. Endocrinol. 20 (2006) 1707-1714
75. Weyant M.J., Carothers A.M., Mahmoud N.N., Bradlow H.L., Remotti H., Bilinski R.T., and Bertagnolli M.M. Reciprocal expression of ERalpha and ERbeta is associated with estrogen-mediated modulation of intestinal tumorigenesis. Cancer Res. 61 (2001) 2547-2551
76. McDonnell D.P., and Norris J.D. Connections and regulation of the human estrogen receptor. Science 296 (2002) 1642-1644
77. Balmer N.N., Richer J.K., Spoelstra N.S., Torkko K.C., Lyle P.L., and Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod. Pathol. 19 (2006) 1593-1605
78. Castiglione F., Taddei A., Degl'Innocenti D.R., Buccoliero A.M., Bechi P., Garbini F., Chiara F.G., Moncini D., Cavallina G., Marascio L., Freschi G., and Gian L.T. Expression of estrogen receptor beta in colon cancer progression. Diagn. Mol. Pathol. 17 (2008) 231-236